0001493152-24-028850.txt : 20240724 0001493152-24-028850.hdr.sgml : 20240724 20240723183706 ACCESSION NUMBER: 0001493152-24-028850 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240724 DATE AS OF CHANGE: 20240723 EFFECTIVENESS DATE: 20240724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hepion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001583771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 462783806 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-519570 FILM NUMBER: 241135746 BUSINESS ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 BUSINESS PHONE: 732-902-4000 MAIL ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 FORMER COMPANY: FORMER CONFORMED NAME: ContraVir Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130806 D 1 primary_doc.xml X0708 D LIVE 0001583771 Hepion Pharmaceuticals, Inc. 399 THORNALL STREET FIRST FLOOR EDISON NJ NEW JERSEY 08837 (732) 902-4000 DELAWARE None ContraVir Pharmaceuticals, Inc. Corporation true John Cavan 399 Thornall Street First Floor Edison NJ NEW JERSEY 08837 Executive Officer Interim Chief Executive Officer and Chief Financial Officer John P. Brancaccio 399 Thornall Street First Floor Edison NJ NEW JERSEY 08837 Director Timothy Block 399 Thornall Street First Floor Edison NJ NEW JERSEY 08837 Director Kaouthar Lbiati 399 Thornall Street First Floor Edison NJ NEW JERSEY 08837 Director Michael Purcell 399 Thornall Street First Floor Edison NJ NEW JERSEY 08837 Director Pharmaceuticals Decline to Disclose 06b false 2024-07-19 false true true true 0 A.G.P./Alliance Global Partners 000008361 None None 88 Post Road West 2nd Floor Westport CT CONNECTICUT 06880 FL FLORIDA NV NEVADA NY NEW YORK true Laidlaw & Company (UK) Ltd. 000119037 None None 521 Fifth Avenue 12th Floor New York NY NEW YORK 10175 FL FLORIDA NV NEVADA NY NEW YORK true 2900000 2900000 0 false 7 175000 0 $52,500 of the reported sales commission was paid to A.G.P./Alliance Global Partners and $122,500 of the reported sales commission was paid to Laidlaw & Company (UK) Ltd. 0 false Hepion Pharmaceuticals, Inc. /s/ John Cavan John Cavan Interim Chief Executive Officer and Chief Financial Officer 2024-07-23